Elecsys® BRAHMS PCT

Elecsys® BRAHMS PCT

 

Elecsys® BRAHMS Procalcitonin (PCT) delivers fully automated, reliable, realtime clinical decision support for the management of sepsis.


 

PCT is a biomarker with high specificity for an inflammatory response to a bacterial infection. PCT concentrations in the blood can aid clinicians in the detection of clinically relevant bacterial infections. PCT is considered a prognostic marker to support outcome prediction in sepsis patients.1,2,3,4

About Sepsis

Sepsis is life threatening organ dysfunction caused by a dysregulated host response to infection.5,6,7 Sepsis and septic shock are major healthcare problems, with more than 1 in 1000 people in developed countries suffering from sepsis each year.8 Early identification and appropriate management in the initial hours after sepsis develops improves outcomes.9

Assay time 18 min.
Sample material Serum collected using standard sampling tubes or tubes containing separating gel. Liheparin, K3‑EDTA plasma.
Sample volume 30 μL
Analytical Sensitivity <0.02 ng/mL
Functional Sensitivity <0.06 ng/mL
Traceabilty Standardized against BRAHMS PCT LIA
Measuring range 0.02-100 ng/mL (defined by the lower detection limit and the maximum of the master curve)

Elecsys BRAHMS PCT helps to improve your sepsis patient management by providing reliable realtime clinical decision support data about a suspected infection, disease severity, and response to treatment.

References

1 Clec’h C, Ferriere F, Karoubi P, et al. Diagnostic and prognostic value of procalcitonin in patients with septic shock. Crit Care Med. 2004;32(5):11661169.
2 Novotny A, Emmanuel K, Matevossian E, et al. Use of procalcitonin for early prediction of lethal outcome of postoperative sepsis. The American Journal of Surgery 2007;194:3539.
3 Hausfater P, Juillien G, MadonnaPy B, et al. Serum procalcitonin measurement as diagnostic and prognostic marker in febrile adult patients presenting to the emergency department. Crit Care. 2007;11(3):6069.
4 Dahaba AA, Hagara B, Fall A, et al. Procalcitonin for early prediction of survival outcome in postoperative critically ill patients with severe sepsis. Br J Anaesth 2006;97:503508.
5 Singer M, Deutschman CS, Seymour CW et al (2016) The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis3). JAMA 315(8):801–810
6 ShankarHari M, Phillips GS, Levy ML et al (2016) Developing a new definition and assessing new clinical criteria for septic shock: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis3). JAMA 315(8):775–787
7 Seymour CW, Liu VX, Iwashyna TJ et al (2016) Assessment of clinical criteria for sepsis: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis3). JAMA 315(8):762–774
8 Issrah Jawad, et al: "Assessing available information on the burden of sepsis: global estimates of incidence, prevalence and mortality." J Glob Health. 2012 Jun; 2(1): 00404
9 Rhodes Andrew et al (2016) Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med DOI 10.1007/s0013401746836